Lenzetto (Estradiol)

Estradiol in Lenzetto penetrates the skin and enters the bloodstream, where it binds to estrogen receptors (ERα and ERβ) in target cells. This receptor complex regulates gene transcription, restoring estrogen‑dependent physiological processes in the brain, bone, skin, and reproductive tissues.

The specific dose and patch change interval for Lenzetto are determined by the prescribing clinician based on the patient’s age, severity of symptoms, and individual risk factors. Healthcare providers select the appropriate strength and schedule to achieve optimal hormonal balance.

Lenzetto is contraindicated in pregnancy because exogenous estrogen can affect fetal development. Its safety during breastfeeding has not been established; therefore, it should be avoided in nursing mothers unless the benefits clearly outweigh potential risks, as decided by a qualified physician.

To order Lenzetto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with oral estradiol tablets, Lenzetto delivers estrogen continuously through the skin, avoiding first‑pass hepatic metabolism and often resulting in more stable serum levels. This route can reduce gastrointestinal side effects and may lower the impact on liver‑produced clotting factors, though individual response varies.

Lenzetto patches should be stored at room temperature, below 25 °C, in their original sealed pouch. Keep them away from direct sunlight, moisture and excessive heat. Do not expose the patch to temperatures above the recommended range, as this could affect drug stability.

Lenzetto is applied to clean, dry, intact skin on the lower abdomen, buttock, or upper arm. The patch is worn for the prescribed duration—typically one week—then removed and replaced with a new patch at a different site to minimize skin irritation.

The most serious risks include thromboembolic events such as deep‑vein thrombosis, stroke, and myocardial infarction, especially in women with pre‑existing cardiovascular risk factors. Rare but severe allergic reactions (anaphylaxis) and hepatic dysfunction have also been reported and require immediate medical attention.

Lenzetto should not be used by women with a history of estrogen‑dependent cancers (e.g., breast or endometrial cancer), active thromboembolic disease, uncontrolled hypertension, or unexplained vaginal bleeding. It is also contraindicated during pregnancy and is generally avoided in breastfeeding mothers unless specifically advised by a physician.